Javier Luna*, Amalia Sotoca, Pablo Fernández, Celia Miralles, Aurora Rodríguez

Luna et al. J Clin Transl Res. 2021; 7(2):10

Published online: April 6, 2021


Treatment of early-stage non-small cell lung cancer has undergone considerable change in recent years. Areas of great interest to researchers include less invasive surgical methods with lower associated morbidity, indications for adjuvant chemotherapy and radiotherapy, the emergence of SBRT for peripheral and central or ultracentral tumors, and the probable role of adjuvant immunotherapy following surgery and SBRT, all of which may influence the management of these patients.
Relevance for patients: Currently, the treatment of early stage non-small cell lung cancer is undergoing changes associated with the evolution of existing treatments and the advent of new treatments.

DOI: http://dx.doi.org/10.18053/jctres.07.202102.010

Author affiliation

1. Radiation Oncology Department, Fundación Jiménez Díaz, Madrid
2. Radiation Oncology Department, Ruber International, Madrid
3. Thoracic Surgery Department, Fundación Jiménez Díaz, Madrid
4. Medical Oncology Department, Ruber Clinic, Madrid

*Corresponding author
Javier Luna
Radiation Oncology Department, Fundación Jiménez Díaz, Madrid. Reyes Católicos Avenue, nº2, 28040 Madrid
Email: jluna@fjd.es

Handeling editor:
Michal Heger
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China


Full text PDF